GENFIT

Audit Report / Information • May 3, 2016

REGULATED INFORMATION RELEASE

GENFIT: FEES GRANTED TO THE STATUTORY AUDITORS

Lille (France), Cambridge (Massachusetts, United States), May 3rd, 2016 – GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced the publication of the fees of the statutory auditors in accordance with article 222-8 of the General Regulation of the French Autorité des marchés financiers.

Fees paid to statutory auditors	Ernst & Young & Autres				Grant Thornton				Aine & Deldicque Associés
	Amount excl. VAT		%		Amount excl. VAT		%		Amount excl. VAT		%
(in € thousands)	2015	2014	2015	2014	2015	2014	2015	2014	2015	2014	2015	2014
Audit
Auditing, certification of
financial statements,
examination of parent
company and consolidated
financial statements
- Issuer	80	78	37%	56%	25	19	84%	100%		0		0%
- Fully consolidated	0	0	0%	0%	0	0	0%	0%		0		0%
subsidiaries
Other tasks and services
directly related to the audit
- Issuer	139	62	63%	44%	5	0	16%	0%		5		100%
- Fully consolidated	0	0	0%	0%	0	0	0%	0%		0		0%
subsidiaries
Sous-total	220	140	100%	100%	30	19	100%	100%		5		100%
Other services provided by
the networks to fully
consolidated subsidiaries
Legal, tax, social	0	0	0%	0%	0	0	0%	0%		0		0%
Others (specifiy if > 10% of	0	0	0%	0%	0	0	0%	0%		0		0%
audition fees)
Sub-total	0	0	0%	0%	0	0	0%	0%		0		0%
Total	220	140	100%	100%	30	19	100%	100%		5		100%

This table is available on the Company's website at www.genfit.com, in the section "Investors/Documentation Center".

*English version for information purposes only.

The table has been translated in English for information purposes only; in the event of any differences between the text in French and the text in English, the French version shall supersede.

REGULATED INFORMATION RELEASE

About GENFIT:

GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH – Nonalcoholic steatohepatitis) and more generally the gastrointestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, Elafibranor, is currently in a Phase 3 study. With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com

Forward Looking Statement / Disclaimer:

This release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, results of clinical data from the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, Elafibranor in NASH and PBC, as well as other indications, and biomarkers, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under Section 4.2 "Risk Factors" ("Facteurs de Risque") of the Company's Annual Financial Report for the year ended December 31, 2015, which is available on GENFIT's website (www.genfit.com). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements.

This release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

CONTACT

GENFIT | Jean-François Mouney – Chairman & CEO | Ph. +333 2016 4000

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com